Androgen misuse and abuse

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 2, 2011, Pages 377-389

  Handelsman, David J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

abuse; anabolic steroid; androgen; andropause; misuse; testosterone

Indexed keywords

ANABOLIC AGENT; ANDROGEN;

DRUG ABUSE; DRUG MARKETING; DRUG USE; HEALTH CARE POLICY; HUMAN; PRESCRIPTION; PREVALENCE; REVIEW; RISK ASSESSMENT;

AGING; ANDROGENS; DOPING IN SPORTS; FEMALE; HUMANS; MALE; SUBSTANCE-RELATED DISORDERS; TESTOSTERONE;

EID: 79952545180     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2010.09.005     Document Type: Review

References (88)

1. Handelsman DJ. Androgen physiology, pharmacology and abuse. In DeGroot LJ & Jameson JL (eds.). Endocrinology. 6th ed. Philadelphia: Elsevier Saunders, 2010, pp. 2469-2498.
2. Hamilton JB. Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 1937; 21: 649-654.
3. Kruskemper HL. Anabolic steroids. New York: Academic Press, 1968.
4. Kochakian CD (ed.). Anabolic-androgenic steroids. Berlin: Springer-Verlag, 1976.
5. Nieschlag E & Behre HM (eds.). Testosterone: action,deficiency, substitution. 3rd ed. Cambridge: Cambridge University Press, 2004.
6. Yesalis CE (ed.). Anabolic steroids in sports and exercise. Champaign: Human Kinetics Publishers Inc, 1993.
7. Butenandt A & Hanisch G. Uber die umwandlung des dehydroandrosterons in androstenol-(17)-one-(3) (testosterone); umweg zur darstellung des testosterons aus cholsterin (vorlauf mitteilung). Zeischrift Physiologische Chemie 1935; 237: 89-97.
8. David K, Dingmanse E, Freud J et al. Uber krystallinisches mannliches hormon aus hoden (Testosteron), wirksamer als aus harn oder aus cholestrin bereites androsteron. Zeischrift Physiologische Chemie 1935; 233: 281-282.
9. Ruzicka L & Wettstein A. Uber die krystallische herstellung des testikelhormons, testosteron (androsten-3-on-17-ol). Helvetica Chimica Acta 1935; 18: 1264-1275.
10. Brown-Sequard CE. Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 1889; 134: 105-107.
11. Sengoopta C. 'Dr Steinach coming to make old young!': sex glands, vasectomy and the quest for rejuvenation in the roaring twenties. Endeavour 2003; 27: 122-126.
12. Wyndham D. Versemaking and lovemaking-W.B. Yeats' "strange second puberty": Norman Haire and the Steinach rejuvenation operation. Journal of the History of the Behavioral Sciences 2003; 39: 25-50.
13. Voronoff S. Rejuvenation by grafting. London: George Allen & Unwin Ltd, 1925.
14. Cussons AJ, Bhagat CI, Fletcher SJ et al. Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. The Medical Journal of Australia 2002; 177: 678-679. (Pubitemid 36040510)
15. Anonymous. Dr Brown-Sequard's "Elixir of life". Lancet 1890; 135: 57-58.
16. Anonymous. The pentacle of rejuvenescence. British Medical Journal 1889; 1: 1416.
17. Borell M. Brown-Sequard's organotherapy and its appearance in America at the end of the nineteenth century. Bulletin of the History of Medicine 1976; 50: 309-320.
18. Borell M. Organotherapy, British physiology, and discovery of the internal secretions. Journal of the History of Biology 1976; 9: 235-268.
19. Liu PY & Handelsman DJ. Androgen therapy in non-gonadal disease. In Nieschlag E & Behre HM (eds.). Testosterone: action, deficiency and substitution. 3rd ed. Berlin: Springer-Verlag, 2004, pp. 445-495.
20. Handelsman DJ. Trends and regional differences in testosterone prescribing in Australia: 1991-2001. The Medical Journal of Australia 2004; 181: 419-422.
21. Osborne V, Hazell L, Layton D et al. Drug utilization of intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management. Drug Safety: An International Journal of Medical Toxicology and Drug Experience 2010; 33: 213-221.
22. Cavanah SF, Jacobson JM & McIntyre T. Clinical use of androgenic steroids at a major medical center: who prescribes androgens and how well do they do it? Journal of Clinical Pharmacology 1993; 33: 253-258.
23. Purcell DW, Wolitski RJ, Hoff CC et al. Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS 2005; 19(Suppl. 1): S57-S66.
24. Katz A & Burchill C. Androgen therapy: testing before prescribing and monitoring during therapy. Canadian Family Physician Médecin de Famille Canadien 2007; 53: 1936-1942. (Pubitemid 351198330)
25. Freeman MP. Testosterone supplementation in women: prescribing practices in one community. Journal of Women's Health 2004; 13: 239-240.
26. Thiblin I & Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundamental & Clinical Pharmacology 2005; 19: 27-44. (Pubitemid 40204345)
27. Liu PY & Handelsman DJ. The present and future state of hormonal treatment for male infertility. Human Reproduction Update 2003; 9: 9-23. (Pubitemid 36305580)
28. Johns K, Beddall MJ & Corrin RC. Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database of Systematic Reviews 2005. CD005483.
29. Buvat J & Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. The Journal of Urology 1997; 158: 1764-1767. (Pubitemid 27433148)
30. Qaseem A, Snow V, Denberg TD et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American college of physicians. Annals of Internal Medicine 2009; 151: 639-649.
31. Bolona ER, Uraga MV, Haddad RM et al. Testosterone use in men with sexual dysfunction: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clinic Proceedings. Mayo Clinic 2007; 82: 20-28. (Pubitemid 46036318)
32. Coviello AD, Lakshman K, Mazer NA et al. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. The Journal of Clinical Endocrinology and Metabolism 2006; 91: 4669-4675. (Pubitemid 44833455)
33. Liverman CT & Blazer DG (eds.). Testosterone and aging: clinical research directions. Washington, DC: Institute of Medicine: The National Academies Press, 2004.
34. Conway AJ, Handelsman DJ, Lording DW et al. Use, misuse and abuse of androgens: the endocrine society of Australia consensus guidelines for androgen prescribing. The Medical Journal of Australia 2000; 172: 220-224. (Pubitemid 30140126)
35. Nieschlag E, Swerdloff R, Behre HM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. International Journal of Andrology 2005; 28: 125-127. (Pubitemid 40780337)
36. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2006; 91: 1995-2010. (Pubitemid 43854972)
37. Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Journal of Andrology 2009; 30: 1-9.
38. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2010; 95: 2536-2559.
39. Shackelton RJ, Marceau LD, Link CL et al. The intended and unintended consequences of clinical guidelines. Journal of Evaluation in Clinical Practice 2009; 15: 1035-1042.
40. Kelleher S, Conway AJ & Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. The Journal of Clinical Endocrinology and Metabolism 2004; 89: 3813-3817. (Pubitemid 39071477)
41. Zitzmann M, Faber S & Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. The Journal of Clinical Endocrinology and Metabolism 2006; 91: 4335-4343. (Pubitemid 44833407)
42. Araujo AB, Esche GR, Kupelian V et al. Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology and Metabolism 2007; 92: 4241-4247. (Pubitemid 350074738)
43. Travison TG, Shackelton R, Araujo AB et al. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. Journal of the American Geriatrics Society 2008; 56: 831-839. (Pubitemid 351652412)
44. Araujo AB, O'Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. The Journal of Clinical Endocrinology and Metabolism 2004; 89: 5920-5926. (Pubitemid 39628393)
45. Wu FC, Tajar A, Beynon JM et al. Identification of late-onset hypogonadism in middle-aged and elderly men. The New England Journal of Medicine 2010.
46. Sikaris K, McLachlan RI, Kazlauskas R et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. The Journal of Clinical Endocrinology and Metabolism 2005; 90: 5928-5936. (Pubitemid 41606507)
47. Taieb J, Mathian B, Millot F et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clinical Chemistry 2003; 49: 1381-1395. (Pubitemid 36900626)
48. Basaria S, Coviello AD, Travison TG et al. Adverse events associated with testosterone administration. The New England Journal of Medicine 2010.
49. Chen DT, Wynia MK, Moloney RM et al. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiology and Drug Safety 2009; 18: 1094-1100.
50. Sjoqvist F, Garle M & Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008; 371: 1872-1882. (Pubitemid 351734542)
51. Handelsman DJ & Heather A. Androgen abuse in sports. Asian Journal of Andrology 2008; 10: 403-415. (Pubitemid 351584116)
52. Franke WW & Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clinical Chemistry 1997; 43: 1262-1279. (Pubitemid 27297278)
53. Kanayama G, Boynes M, Hudson JI et al. Anabolic steroid abuse among teenage girls: an illusory problem? Drug and Alcohol Dependence 2007; 88: 156-162.
54. Handelsman DJ & Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian secondary school students. International Journal of Andrology 1997; 20: 159-164. (Pubitemid 27470087)
55. Yesalis CE (ed.). Anabolic steroids in sports and exercise. 2nd ed. Champaign: Human Kinetics Publishers Inc, 2000.
56. Yesalis CE, Kennedy NJ, Kopstein AN et al. Anabolic-androgenic steroid use in the United States. Journal of the American Medical Association 1993; 270: 1217-1221. (Pubitemid 23262352)
57. Johnston LD, O'Malley PM, Bachman JG et al. Secondary school students. In: . Monitoring the future national survey results on drug use, 1975-2005 2008; vol. I. Bethesda: National Institute on Drug Abuse, 2008.
58. Elashoff JD, Jacknow AD, Shain SG et al. Effects of anabolic-androgenic steroids on muscular strength. Annals of Internal Medicine 1991; 115: 387-393.
59. Bhasin S, Storer TW, Berman N et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. The New England Journal of Medicine 1996; 335: 1-7. (Pubitemid 26230806)
60. Bhasin S,Woodhouse L, Casaburi R et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. The Journal of Clinical Endocrinology and Metabolism 2005; 90: 678-688. (Pubitemid 40279179)
61. Storer TW, Woodhouse L, Magliano L et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. Journal of the American Geriatrics Society 2008.
62. Ishak KG & Zimmerman HJ. Hepatotoxic effects of the anabolic-androgenic steroids. Seminars in Liver Disease 1987; 7: 230-236.
63. Carrasco D, Prieto M, Pallardo L et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate Review of the literature. Journal of Hepatology 1985; 1: 573-578.
64. Pope Jr. HG, Kouri EM & Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Archives of General Psychiatry 2000; 57: 133-140. Discussion 55-56.
65. Melchert RB & Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Medicine and Science in Sports and Exercise 1995; 27: 1252-1262.
66. Handelsman DJ. Testosterone and male ageing: spinning the wheels. The Medical journal of Australia 2010; 193: 379-380.
67. Hartgens F, Cheriex EC & Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. International Journal of Sports Medicine 2003; 24: 344-351. (Pubitemid 36936451)
68. Chung T, Kelleher S, Liu PY et al. Effects of testosterone and nandrolone on cardiac function: a randomized, placebocontrolled study. Clinical Endocrinology 2007; 66: 235-245. (Pubitemid 46096144)
69. Liu PY, Death AK & Handelsman DJ. Androgens and cardiovascular disease. Endocrine Reviews 2003; 24: 313-340. (Pubitemid 36724373)
70. Jin B, Turner L, Walters WAW et al. Androgen or estrogen effects on the human prostate. The Journal of Clinical Endocrinology and Metabolism 1996; 81: 4290-4295. (Pubitemid 26412031)
71. Van Eenoo P & Delbeke FT. Metabolism and excretion of anabolic steroids in doping control - new steroids and new insights. The Journal of Steroid Biochemistry and Molecular Biology 2006; 101: 161-178. (Pubitemid 44573810)
72. Kicman AT. Pharmacology of anabolic steroids. British Journal of Pharmacology 2008; 154: 502-521. (Pubitemid 351744954)
73. Schanzer W. Abuse of androgens and detection of illegal use. In Nieschlag E & Behre HM (eds.). Testosterone: action deficiency substitution. 3rd ed. Cambridge: Cambridge University Press, 2004, pp. 715-735.
74. Goldberg L, MacKinnon DP, Elliot DL et al. The adolescents training and learning to avoid steroids program: preventing drug use and promoting health behaviors. Archives of Pediatrics & Adolescent Medicine 2000; 154: 332-338. (Pubitemid 30198478)
75. DuRant RH, Rickert VI, Ashworth CS et al. Use of multiple drugs among adolescents who use anabolic steroids. The New England Journal of Medicine 1993; 328: 922-926. (Pubitemid 23086644)
76. Kokkevi A, Fotiou A, Chileva A et al. Daily exercise and anabolic steroids use in adolescents: a cross-national European study. Substance Use & Misuse 2008; 43: 2053-2065.
77. Kanayama G, Cohane GH, Weiss RD et al. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? The Journal of Clinical Psychiatry 2003; 64: 156-160. (Pubitemid 36268318)
78. Kanayama G, Brower KJ, Wood RI et al. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 2009; 104: 1966-1978.
79. McCabe SE, Brower KJ, West BT et al. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug and Alcohol Dependence 2007; 90: 243-251. (Pubitemid 47287715)
80. Melia P, Pipe A & Greenberg L. The use of anabolic-androgenic steroids by Canadian students. Clinical Journal of Sport Medicine 1996; 6: 9-14. (Pubitemid 26104556)
81. Dal Pizzol Tda S, Branco MM, Carvalho RM et al. [Non-medical use of psychoactive medicines among elementary and high school students in Southern Brazil]. Cadernos De Saúde Pública 2006; 22: 109-115.
82. De Micheli D & Formigoni ML. Drug use by Brazilian students: associations with family, psychosocial, health, demographic and behavioral characteristics. Addiction 2004; 99: 570-578. (Pubitemid 38561420)
83. Schwellnus MP, Lambert MI, Todd MP et al. Androgenic anabolic steroid use in matric pupils. South African Medical Journal 1992; 82: 154-158.
84. Lambert MI, Titlestad SD & Schwellnus MP. Prevalence of androgenic-anabolic steroid use in adolescents in two regions of South Africa. South African Medical Journal 1998; 88: 876-880. (Pubitemid 28379234)
85. Nilsson S. Androgenic anabolic steroid use among male adolescents in Falkenberg. European Journal of Clinical Pharmacology 1995; 48: 9-11.
86. Kindlundh AM, Isacson DG, Berglund L et al. Doping among high school students in Uppsala, Sweden: a presentation of the attitudes, distribution, side effects, and extent of use. Scandinavian Journal of Social Medicine 1998; 26: 71-74.
87. Wanjek B, Rosendahl J, Strauss B et al. Doping, drugs and drug abuse among adolescents in the state of Thuringia (Germany): prevalence, knowledge and attitudes. International Journal of Sports Medicine 2007; 28: 346-353. (Pubitemid 46640303)
88. Pallesen S, Josendal O, Johnsen BH et al. Anabolic steroid use in high school students. Substance Use & Misuse 2006; 41: 1705-1717. (Pubitemid 44844159)